{"title":"胃癌与QIAPI病例报告","authors":"A. Herrera, Nicolas Saavedra Rojas","doi":"10.33425/2639-9334.1061","DOIUrl":null,"url":null,"abstract":"Despite significant therapeutic progress, gastric cancer remains among the deadliest forms of cancer encountered in clinical practice, and this remains true even in the context of declining incidence. Outcomes in advanced disease remain poor and therapy is rarely curative in this setting. Different therapies have developed in the hopes of altering nearly uniformly poor outcomes.","PeriodicalId":338144,"journal":{"name":"Gastroenterology, Hepatology & Digestive Disorders","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gastric Cancer and QIAPI, Case Report\",\"authors\":\"A. Herrera, Nicolas Saavedra Rojas\",\"doi\":\"10.33425/2639-9334.1061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite significant therapeutic progress, gastric cancer remains among the deadliest forms of cancer encountered in clinical practice, and this remains true even in the context of declining incidence. Outcomes in advanced disease remain poor and therapy is rarely curative in this setting. Different therapies have developed in the hopes of altering nearly uniformly poor outcomes.\",\"PeriodicalId\":338144,\"journal\":{\"name\":\"Gastroenterology, Hepatology & Digestive Disorders\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology, Hepatology & Digestive Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33425/2639-9334.1061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology, Hepatology & Digestive Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33425/2639-9334.1061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Despite significant therapeutic progress, gastric cancer remains among the deadliest forms of cancer encountered in clinical practice, and this remains true even in the context of declining incidence. Outcomes in advanced disease remain poor and therapy is rarely curative in this setting. Different therapies have developed in the hopes of altering nearly uniformly poor outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
